恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2022.04.009

摘要/Abstract

摘要： 目的探讨应用恩替卡韦(ETV)联合聚乙二醇干扰素α-2b(PEG-IFNα-2b)治疗血清低水平HBsAg阳性的慢性乙型肝炎(CHB)患者的临床疗效。方法 2018年1月～2020年1月我院收治的CHB患者96例,采用随机数字表法分成对照组48例和观察组48例,分别给予ETV或ETV联合PEG-IFNα-2b治疗观察48 w。采用荧光定量PCR法检测HBV DNA定量,采用电化学发光法检测血清HBsAg和HBeAg水平,使用流式细胞仪检测外周血CD3⁺、CD4⁺和CD8⁺细胞百分比,并计算CD4⁺/CD8⁺细胞比值。结果在治疗48 w末,观察组血清HBsAg和HBeAg水平分别为(809.8±101.5)IU/mL和(193.4±24.5)IU/mL,均显著低于对照组【分别为(1201.7±204.9)IU/mL和(244.2±5.7)IU/mL,P<0.05】;观察组血清HBeAg转阴率为29.2%,显著高于对照组的4.2%(P<0.05),血清HBeAg转换率为12.5%,血清HBsAg转阴率为8.3%;观察组血清ALT和AST水平分别为(52.5±4.6)U/L和(45.1±5.2)U/L,均显著低于对照组【分别为(63.4±5.2)U/L和(68.2±5.4)U/L,P<0.05】;观察组外周血CD3⁺、CD4⁺细胞百分比和CD4⁺/CD8⁺细胞比值分别为(68.5±4.2)%、(38.1±3.6)%和(1.8±0.5),均显著高于对照组【分别为(57.4±3.8)%、(32.6±3.1)%和(1.1±0.4),P<0.05】,而CD8⁺细胞百分比为(21.3±1.8)%,显著低于对照组【(28.7±2.0)%,P<0.05】。结论应用ETV联合PEG-IFNα-2b治疗血清低水平HBsAg阳性的CHB患者具有较好的抗病毒疗效,在部分患者获得了血清学应答,可能与应用α-干扰素提高了机体免疫功能有关。

关键词: 慢性乙型肝炎, 恩替卡韦, 聚乙二醇干扰素α-2b, HBsAg, 治疗

Abstract: Objective The aim of this study was to explore the antiviral efficacy of entecavir (ETV) and pegylated interferon α-2b (PEG-IFNα-2b) combination in treatment of patients with low serum level HBsAg-positive chronic hepatitis B (CHB). Methods A total of 96 patients with low serum level HBsAg-positive CHB were enrolled in our hospital between January 2018 and January 2020, and were randomly divided into control and observation group, with 48 cases in each group. The patients in the control group were treated with orally ETV and those in the observation were treated with ETV and PEG-IFNα-2b combination for 48 weeks. Serum HBV DNA loads were detected by fluorescence quantitative polymerase chain reaction, and serum HBsAg and HBeAg levels were detected by electrochemiluminescence. The percentages of CD3⁺, CD4⁺ and CD8⁺ cells were detected by flow cytometry, and ratio of CD4⁺/CD8⁺ cells was calculated. Results At the end of 48 week observation, serum HBsAg and HBeAg levels in the observation group were (809.8±101.5)IU/mL and (193.4±24.5)IU/mL, both significantly lower than [(1201.7±204.9)IU/mL and (244.2±5.7)IU/mL, respectively, P<0.05] in the control; serum HBeAg negative rate was 29.2%, significantly higher than 4.2%(P<0.05) in the control, and the HBeAg seroconversion rate was 12.5% and serum HBsAg loss was 8.3%; serum ALT and AST levels were (52.5±4.6)U/L and (45.1±5.2)U/L, both significantly lower than [(63.4±5.2)U/L and (68.2±5.4)U/L, respectively, P<0.05] in the control; the percentages of peripheral blood CD3⁺ and CD4⁺ cells and the ratio of CD4⁺/CD8⁺ cells were (68.5±4.2)%, (38.1±3.6)% and (1.8±0.5), all significantly higher than [(57.4±3.8)%, (32.6±3.1)% and (1.1±0.4), respectively, P<0.05], while the percentage of CD8⁺ cells was(21.3±1.8)%, significantly lower than [(28.7±2.0)%, P<0.05] in the control group. Conclusion The regimen with ETV and PEG-IFNα-2b combination in treating CHB patients with low serum HBsAg positive could gain a good antiviral efficacy, with serologic response in some cases, which might be related to the improved immune functions.

Key words: Hepatitis B, Entecavir, Pegylated interferon α-2b, HBsAg, Antiviral response

贾婷, 李俊义, 张秀灵, 高斯媛, 杨婧, 杨晓冬. 恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 488-491.

Jia Ting, Li Junyi, Zhang Xiuling, et al. Serologic response toentecavir and pegylated interferon α-2b combination in treatment of patients with low serum level HBsAg-positive chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(4): 488-491.

参考文献

[1] Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021,6(2):106-119.
[2] Huang Q, Zhou B, Cai D, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients. Hepatology, 2021,73(1):41-52.
[3] Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020,(12):1039-1052.
[4] He Y, Yin J, Xu H. Efficacy and safety of pegylated interferon for the treatment of chronic hepatitis B in children and adolescents: A systematic review and meta-analysis. Pediatr Infect Dis J, 2020,39(12):1121-1126.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[6] 蒋奕, 刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析. 实用肝脏病杂志, 2019, 22(2):42-45.
[7] Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: A systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2021,19(2):246-258.
[8] Li ZB, Li L, Niu XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021,41(6):1254-1264.
[9] Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology, 2021,73(2):661-673.
[10] Mimura S, Fujita K, Takuma K, et al. Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. Intern Emerg Med, 2021,16(6):1559-1565.
[11] 段树鹏, 朱利红, 侯丽娟, 等. HBcAg特异性Th9细胞在乙型肝炎病毒感染者中的免疫调控作用. 中华微生物学和免疫学杂志, 2021, 41(8):608-615.
[12] Papatheodoridis GV, Voulgaris T, Papatheodoridi M, et al. Risk scores for hepatocellular carcinoma in chronic hepatitis B: A promise for precision medicine. Hepatology, 2020,72(6):2197-2205.
[13] Chan HLY, Yasuda S, Wong GLH, et al. Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. J Gastroenterol Hepatol, 2020,35(12):2202-2209.
[14] Lu YX, He CZ, Wang YX, et al. Effect of entecavir on the intestinal microflora in patients with chronic hepatitis B: A controlled cross-sectional and longitudinal real-world study. Infect Dis Ther, 2021,10(1):241-252.
[15] Belopolskaya M, Avrutin V, Kalinina O, et al. Chronic hepatitis B in pregnant women: Current trends and approaches. World J Gastroenterol, 2021,27(23):3279-3289.
[16] Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology, 2021,73(6):2167-2179.
[17] Zeng W, Liu M, Peng S, et al. Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients? J Viral Hepat, 2020,27(12):1509-1510.
[18] Chen S, Zhou J, Wu X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int, 2021,15(3):611-620.
[19] Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B. Clin Infect Dis, 2021,72(2):202-211.
[20] Hu TH, Yueh-Hsia Chiu S, Tseng PL, et al. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther, 2020,52(11-12):1695-1706.
[21] Lin MT, Chang KC, Yen YH, et al. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc, 2021,120(1 Pt 3):621-628.
[22] 罗丹, 陈勇, 陈清,等. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者外周血T淋巴细胞亚群和血清细胞因子水平变化. 实用肝脏病杂志, 2018, 21(2):53-56.

恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究^*

Serologic response toentecavir and pegylated interferon α-2b combination in treatment of patients with low serum level HBsAg-positive chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘霖, 胡蕴, 许岚. 糖脂代谢紊乱相关疾病患者生活方式管理现状和研究进展^*[J]. 实用肝脏病杂志, 2022, 25(4): 464-467.
[2]	刘雨莹, 张娇珍, 周海娟, 潘芳蝶, 黎才丽, 钟昌宝. 替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 492-495.
[3]	徐欢, 王广丽, 董丹丹, 黄荷. 聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 500-503.
[4]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[5]	季雪纯, 金世柱, Nepal Narayan, 李宁, 杨宁宁, 张思佳, 林秋池, 陈浩源. 高位食管静脉曲张破裂出血患者内镜诊治经验:10年单中心回顾性分析[J]. 实用肝脏病杂志, 2022, 25(4): 530-533.
[6]	汤磊, 彭蕾, 叶珺, 张振华, 邹桂舟. 影响慢性乙型肝炎患者进展为肝硬化的多因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 538-541.
[7]	刘浩, 周菲菲, 孙好凯, 刘永刚. 基于CBCT的三维重建技术用于TACE术治疗原发性肝癌患者对肿瘤供血动脉识别的价值^*[J]. 实用肝脏病杂志, 2022, 25(4): 563-566.
[8]	张静, 林铤, 孙翔. 超声引导下穿刺抽液联合聚桂醇置换冲洗硬化治疗巨大肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 571-574.
[9]	林益坤, 谢朗, 符剑鸣, 崔春晖. 肝部分切除联合胆肠吻合术治疗肝内胆管结石患者临床疗效及术后结石复发危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 591-594.
[10]	黄鹏, 孟凡斌, 张晓农, 于延铭. 3D模型指导下PTCSL微创治疗复杂性肝胆管结石患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 595-598.
[11]	邹吉, 陈晓波, 董仁华, 张浩. 胆囊切除联合肝组织楔形切除和区域淋巴结清扫治疗胆囊癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 599-602.
[12]	魏博文, 任峥, 张亮, 汪伟. 增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析[J]. 实用肝脏病杂志, 2022, 25(4): 603-604.
[13]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[14]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[15]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.